XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.2
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues Based on Patient Location (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation of Revenue [Line Items]        
Revenue $ 595,275 $ 533,798 $ 1,191,690 $ 1,053,157
ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue 40,318 37,327 74,721 61,709
Product        
Disaggregation of Revenue [Line Items]        
Revenue 584,698 517,660 1,171,124 1,023,185
Marketed by Company | Products excluding ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue 544,380 480,333 1,096,403 961,476
Marketed by Company | Products excluding ALDURAZYME | United States        
Disaggregation of Revenue [Line Items]        
Revenue 191,655 169,838 358,439 320,653
Marketed by Company | Products excluding ALDURAZYME | Europe        
Disaggregation of Revenue [Line Items]        
Revenue 183,434 161,231 344,126 318,062
Marketed by Company | Products excluding ALDURAZYME | Latin America        
Disaggregation of Revenue [Line Items]        
Revenue 75,444 89,911 143,192 152,455
Marketed by Company | Products excluding ALDURAZYME | Middle East        
Disaggregation of Revenue [Line Items]        
Revenue 25,630 21,414 117,272 87,021
Marketed by Company | Products excluding ALDURAZYME | Rest of world        
Disaggregation of Revenue [Line Items]        
Revenue 68,217 37,939 133,374 83,285
Marketed by Sanofi | ALDURAZYME        
Disaggregation of Revenue [Line Items]        
Revenue $ 40,318 $ 37,327 $ 74,721 $ 61,709